In theory Aegerion could still reach this peaks sales figure (quite easily) given that there are many more reimbursable HoFH patients out there, but it appears that Amgen’s (AMGN) hugely successful PCSK9 inhibitor evolocumab will dethrone Juxtapid before that happens.
f Ariad continued to see high rates of Iclusig-induced serious adverse events and/or deaths amongst cancer patients in its new trials, the stock could be in serious trouble.
Read below for more on this stock, which has climbed so much year-to-date and seems to potentially be priced to perfection.
Perhaps the most promising target in the ISIS pipeline is ApoCIII – a protein that is responsible for transporting triglycerides in the blood.
But with the recent loss of its lawsuit against the FDA's approval of these generic (which was meant to block competing glatiramer acetate formulations without additional bioequivalency trial data) it’s clear that the new 40 mg/mL formulation of Copaxone is now the only thing preventing Teva’s Copaxone brand from totally losing its market share in multiple sclerosis given its current price.
A total of seven litigations against Questcor are currently underway. Two of them - the Retrophin litigation and USAO litigation - represent very serious threats to the H.P. Acthar business model.
Perhaps the most important part of the Onyx acquisition was Kyprolis – a blood cancer drug that is currently being marketed as a last resort option for multiple myeloma patients.
Given the data that have been released so far, it appears that the discovery of the PD-1/PD-L1 mechanism is the single biggest technological leap in the immunotherapy space to date.
But despite all the challenging facing Bristol-Myers today, I do believe the positioned to do extremely well in oncology due to the commercial potential of Sprycel (dasatinib) and Yervoy (ipilimumab). Both drugs have been growing sales rapidly throughout the last year, and have no patent concerns in the short run.
If we go all the way back to 1994, we can see that SIAL and TMO appreciated by 905% and 620% - beating the 343% returns seen on the S&P 500.
Merck has been taking heat for the price it paid for Idenix -- Here's why it actually isn't as crazy as it sounds.